Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases.
5.12.16- Aegerion Pharmaceuticals Announces Preliminary Agreements in Principle with DOJ and SEC Related to Ongoing Investigation
2.29.16 - Aegerion Pharmaceuticals Observes Rare Disease Day
1.7.16 - Aegerion Pharmaceuticals Appoints Mary Szela as Chief Executive Officer
11.20.15 - JUXTAPID™ (lomitapide) Capsules Available on the Régie de l'Assurance Maladie du Québec (RAMQ) for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
11.10.15 - Aegerion Pharmaceuticals Announces Results from First Year of LOWER Study at AHA Scientific Sessions 2015
© 2012 Aegerion Pharmaceuticals, Inc. All rights reserved. AEGR/Global/167 07-14